Cubist Systematic Strategies LLC Invests $902,000 in Immunome, Inc. (NASDAQ:IMNM)

Cubist Systematic Strategies LLC purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 84,930 shares of the company's stock, valued at approximately $902,000. Cubist Systematic Strategies LLC owned about 0.11% of Immunome at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of Immunome by 6.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock valued at $359,000 after buying an additional 1,520 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Immunome by 11.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company's stock valued at $202,000 after buying an additional 2,000 shares in the last quarter. Intech Investment Management LLC increased its holdings in Immunome by 26.5% in the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company's stock valued at $201,000 after acquiring an additional 3,974 shares during the last quarter. Wellington Management Group LLP increased its holdings in Immunome by 3.5% in the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after acquiring an additional 4,874 shares during the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Immunome by 17.7% in the 4th quarter. MetLife Investment Management LLC now owns 35,619 shares of the company's stock valued at $378,000 after acquiring an additional 5,354 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Wedbush reiterated an "outperform" rating and issued a $21.00 price target (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Lifesci Capital assumed coverage on shares of Immunome in a report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price target on the stock. Lake Street Capital assumed coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price target on the stock. Finally, Stephens reiterated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.33.

Immunome Price Performance

Shares of Immunome stock traded up $0.21 during trading hours on Tuesday, reaching $8.22. The company's stock had a trading volume of 99,923 shares, compared to its average volume of 916,765. The firm has a 50 day moving average price of $7.62 and a 200-day moving average price of $9.77. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.81. The stock has a market cap of $715.15 million, a P/E ratio of -1.01 and a beta of 2.00.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.46 million. As a group, sell-side analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Clay B. Siegall purchased 137,100 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $7.29 per share, with a total value of $999,459.00. Following the purchase, the chief executive officer now owns 806,736 shares in the company, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Philip Tsai acquired 12,300 shares of the stock in a transaction on Monday, March 24th. The stock was bought at an average cost of $8.42 per share, with a total value of $103,566.00. Following the completion of the transaction, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. This trade represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 156,400 shares of company stock valued at $1,160,495. Company insiders own 8.60% of the company's stock.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.